



ORIGIN
THERAPEUTICS

We provide early access to privately-held, rapidly growing companies in the psychedelic space.

Hundreds of new companies have emerged in the psychedelic industry, each seeking early seed funding from venture capitalists. Now, retail investors can buy in to some of today's most promising private deals with Origin Therapeutics.

CSE: ORIG*
*Proposed Ticker

1.05 Billion people could benefit from psychedelics

Despite the commercial success of conventional medications to treat mental illness and addiction, many leading experts have been disappointed with their efficacy. Researchers are turning to the psychedelic industry for novel treatment options.

164M

PEOPLE AFFECTED BY
SUBSTANCE ABUSE

264M

PEOPLE AFFECTED BY
ANXIETY

300M

PEOPLE AFFECTED BY
POST-TRAUMATIC STRESS

322M

PEOPLE AFFECTED BY
DEPRESSION

↑ **16.3%**

**COST-ADJUSTED ANNUAL GROWTH RATE
FOR THE GLOBAL PSYCHEDELIC MARKET
BETWEEN 2021 - 2027**


Investment Strategy

We seek high returns by making investments in companies involved in the psychedelic and biotechnology industry, particularly those in early stages of development.

A key aspect of our strategy involves finding undervalued companies with strong management teams and solid business models that could benefit from our strategic relationships.

We expect to be an active partner with our target companies, where involvement could make a significant difference in the success and appreciation of our investments.

We aim to contribute in multiple ways by offering guidance, industry knowledge, and additional management expertise to our partner companies.





Portfolio

Dimensions Health Centers

Dimensions Health is focused on developing psychedelic inspired retreats, starting with its flagship property in Maple Lake, Ontario. Origin invested in Dimension's initial seed round and provided guidance on its real estate financing initiatives. Dimensions is currently raising \$12.5M in its Series A round, representing a 3x unrealized return on Origin's initial investment.

Microdose

MicroDose is a psychedelic industry-focused media company that distributes and creates compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine. Origin provided seed capital to MicroDose.

TripSitter

TripSitter is an oral ketamine treatment program delivered online by licensed physicians. TripSitter's program provides deep and sustained relief for both mild and severe depression, anxiety, and trauma-related mental health conditions.

Xpira Pharmaceuticals

Xpira is focused on the development, production, and marketing of psychedelic-based products, as legally permitted, with clinically proven efficacy. Xpira's team was formed by leaders in the Canadian and Dutch pharmaceutical industries with proven track records and a deep understanding of the pharmaceutical development pathways to bring drug candidates to market.

Ocean Bio

Ocean is an early-stage drug discovery company that is focused on the design of novel psychedelic therapeutics (as compared to using traditional psychedelics, such as psilocybin, LSD, ketamine, etc.). Ocean's mission is to develop novel CNS drugs, as legally permitted, that may have desirable therapeutic applications, while minimizing possible negative side effects that are otherwise associated with traditional psychedelics.

Why invest in Origin?

Origin is an actively-managed portfolio and offers investors access to early-stage psychedelic companies, often at the seed or founder's level. Origin supports its investee companies with Board and advisory oversight, with the goal of providing near-term liquidity events for Origin shareholders. Origin does not charge a management fee and is aligned with shareholders to create intrinsic value with equity performance.



**DIVERSIFIED
PORTFOLIO**



**BOARD
REPRESENTATION**



**ACTIVELY
MANAGED**



**NO
MANAGEMENT FEES**



Capitalization

SHARES OUTSTANDING	
FOUNDERS / BOARD OF DIRECTORS / MANAGEMENT	34,000,000
\$5M+ FINANCING @ \$0.25 ¹	20,000,000+
TOTAL	54,000,000
OPTIONS	5,400,000
TOTAL DILUTED	59,400,000

¹Financing is structured as a \$0.25 special warrant. The Company intends to use the proceeds of the financing for investments, general working capital, and listing on a publicly-traded stock exchange.

Managed and directed by a powerhouse team

The members of Origin's Board and management team have been involved in some of the fastest growing companies in their respective industries.



Alexander Somjen
CEO, Director



Kelvin Lee
CFO



Alfred Wong
VP Investments



Michael Young
Chairman



Brianna Davies
Independent Director



About Us

Origin Therapeutics is an actively-managed investment issuer providing investors with a diverse exposure to the psychedelic industry. We focus on companies with an exemplary management team and exponential growth profile.

Contact

General information
info@originpsychedelics.com

Mailing Address
Suite 1570 – 505 Burrard Street
Vancouver, B.C. V7X 1M5